207_Combined course Presentations

EORTC 26053-22054/NCI-C/RTOG 0834 (CATNON) study on Anaplastic Gliomas without 1p/19q loss: 2 x 2 design

R A N D O M I Z A T I O N

RT 59.4 Gy + concurrent temozolomide

Adjuvant temozolomide

SURGERY

Follow-up

No Adjuvant therapy

RT 59.4 Gy

• Primary endpoint: overall survival • Secondary endpoints: - Progression-free survival - Quality of life

• Pre-study 1p/19q testing • Stratification: - Methylation status

- Neurological deterioration free survival